Literature DB >> 2827930

Beta-sympathomimetic agents: use in perinatal obstetrics.

B Nuwayhid1, M Rajabi.   

Abstract

Beta-sympathomimetic agents are used extensively in obstetrics to inhibit premature labor. Knowledge of the pharmacology, mode of action on smooth muscle, and cardiovascular and metabolic side effects of these agents is essential for the obstetrician and perinatologist. This review article draws extensively on recent animal research data to explain mechanisms of action and long-term effects of beta-sympathomimetic agents.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2827930

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN： 0095-5108            Impact factor:   3.430


  4 in total

1.  Targeted sequencing of NOTCH signaling pathway genes and association analysis of variants correlated with mandibular prognathism.

Authors:  Xianzhuo Han; Xueyan Xiong; Xiujuan Shi; Fengshan Chen; Yongming Li
Journal:  Head Face Med       Date:  2021-05-26       Impact factor: 2.151

2.  The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He; Lieven Thorrez; Geraldine Siegfried; Sandra Meulemans; Serge Evrard; Sabine Tejpar
Journal:  Oncogene       Date:  2020-03-06       Impact factor: 9.867

Review 3.  Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects.

Authors:  B Ostádal; V Pelouch; I Ostádalová; O Nováková
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

4.  NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating Akt pathway.

Authors:  Wei Kang; Jinglin Zhang; Tingting Huang; Yuhang Zhou; Chi Chun Wong; Ronald C K Chan; Yujuan Dong; Feng Wu; Bin Zhang; William K K Wu; Michael W Y Chan; Alfred S L Cheng; Jun Yu; Nathalie Wong; Kwok Wai Lo; Ka Fai To
Journal:  Oncogene       Date:  2021-01-15       Impact factor: 9.867
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.